Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Baxter
Julphar
Daiichi Sankyo
Queensland Health
Chubb
AstraZeneca
Deloitte
Cantor Fitzgerald
Boehringer Ingelheim

Generated: December 12, 2017

DrugPatentWatch Database Preview

Isradipine - Generic Drug Details

« Back to Dashboard

What are the generic sources for isradipine and what is the scope of isradipine patent protection?

Isradipine
is the generic ingredient in three branded drugs marketed by Smithkline Beecham, Elite Labs Inc, Watson Labs Teva, Glaxosmithkline Llc, and Mylan Pharms Inc, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for isradipine. Five suppliers are listed for this compound.

Pharmacology for isradipine

Medical Subject Heading (MeSH) Categories for isradipine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Watson Labs TevaISRADIPINEisradipineCAPSULE;ORAL077317-002Jan 5, 2006ABRXNoYes► Subscribe► Subscribe► Subscribe► Subscribe
Smithkline BeechamDYNACIRCisradipineCAPSULE;ORAL019546-002Dec 20, 1990DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Mylan Pharms IncISRADIPINEisradipineTABLET, EXTENDED RELEASE;ORAL201067-001Nov 27, 2015RXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Elite Labs IncISRADIPINEisradipineCAPSULE;ORAL077169-001Apr 24, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Smithkline BeechamDYNACIRCisradipineCAPSULE;ORAL019546-001Dec 20, 1990DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Elite Labs IncISRADIPINEisradipineCAPSULE;ORAL077169-002Apr 24, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Glaxosmithkline LlcDYNACIRC CRisradipineTABLET, EXTENDED RELEASE;ORAL020336-002Jun 1, 1994DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Glaxosmithkline LlcDYNACIRC CRisradipineTABLET, EXTENDED RELEASE;ORAL020336-001Jun 1, 1994DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Watson Labs TevaISRADIPINEisradipineCAPSULE;ORAL077317-001Jan 5, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Mylan Pharms IncISRADIPINEisradipineTABLET, EXTENDED RELEASE;ORAL201067-002Nov 27, 2015RXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: isradipine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline LlcDYNACIRC CRisradipineTABLET, EXTENDED RELEASE;ORAL020336-001Jun 1, 1994► Subscribe► Subscribe
Glaxosmithkline LlcDYNACIRC CRisradipineTABLET, EXTENDED RELEASE;ORAL020336-002Jun 1, 1994► Subscribe► Subscribe
Smithkline BeechamDYNACIRCisradipineCAPSULE;ORAL019546-001Dec 20, 1990► Subscribe► Subscribe
Glaxosmithkline LlcDYNACIRC CRisradipineTABLET, EXTENDED RELEASE;ORAL020336-001Jun 1, 1994► Subscribe► Subscribe
Glaxosmithkline LlcDYNACIRC CRisradipineTABLET, EXTENDED RELEASE;ORAL020336-002Jun 1, 1994► Subscribe► Subscribe
Glaxosmithkline LlcDYNACIRC CRisradipineTABLET, EXTENDED RELEASE;ORAL020336-002Jun 1, 1994► Subscribe► Subscribe
Glaxosmithkline LlcDYNACIRC CRisradipineTABLET, EXTENDED RELEASE;ORAL020336-001Jun 1, 1994► Subscribe► Subscribe
Glaxosmithkline LlcDYNACIRC CRisradipineTABLET, EXTENDED RELEASE;ORAL020336-001Jun 1, 1994► Subscribe► Subscribe
Glaxosmithkline LlcDYNACIRC CRisradipineTABLET, EXTENDED RELEASE;ORAL020336-002Jun 1, 1994► Subscribe► Subscribe
Glaxosmithkline LlcDYNACIRC CRisradipineTABLET, EXTENDED RELEASE;ORAL020336-001Jun 1, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Dow
Cerilliant
Medtronic
Moodys
Mallinckrodt
Queensland Health
Merck
US Army
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot